Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
暂无分享,去创建一个
R. Houlston | K. Eckardt | F. Richards | S. Clifford | M. Wiesener | E. Maher | F. Latif | M. Morris | M. Zatyka | N. F. da Silva
[1] J. Cuzick. A Wilcoxon-type test for trend. , 1985, Statistics in medicine.
[2] R A Laskey,et al. S phase of the cell cycle. , 1989, Science.
[3] J. Blay,et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.
[4] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[5] M. Ferguson-Smith,et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.
[6] R. Sutherland,et al. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[8] J. Herman,et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] N Thatcher,et al. Alternate splicing produces a novel cyclin D1 transcript. , 1995, Oncogene.
[10] B. Ponder,et al. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. , 1995, JAMA.
[11] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[12] S. Akira,et al. Interleukin-6 family of cytokines and gp130. , 1995, Blood.
[13] W. Kaelin,et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[14] C. Kielty,et al. Type VIII collagen is a product of vascular smooth-muscle cells in development and disease. , 1996, The Biochemical journal.
[15] M. Goldberg,et al. Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein* , 1996, The Journal of Biological Chemistry.
[16] R. Klausner,et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Klausner,et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[18] S. Clifford,et al. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL‐independent pathway in clear cell renal tumourigenesis , 1998 .
[19] M. Amin,et al. Cyclin D1 expression in renal carcinomas and oncocytomas: an immunohistochemical study. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[20] V. Sukhatme,et al. Transforming Growth Factor α Is a Target for the Von Hippel-Lindau Tumor Suppressor , 1998 .
[21] K. Branigan,et al. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] W. Kaelin,et al. The VHL tumour-suppressor gene paradigm. , 1998, Trends in genetics : TIG.
[23] W. Kaelin,et al. Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.
[24] A. Harris,et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. , 1998, Blood.
[25] R. Klausner,et al. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Louis,et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.
[27] A. Webster,et al. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. , 1998, American journal of human genetics.
[28] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[29] G. Landberg,et al. Cyclin‐D1 expression in human renal‐cell carcinoma , 1999, International journal of cancer.
[30] J. Foekens,et al. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. , 1999, Cancer research.
[31] A. Webster,et al. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. , 1999, Archives of ophthalmology.
[32] F. C. Lucibello,et al. Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation , 1999, Oncogene.
[33] A. Marotta,et al. Differential cyclin-dependent kinase expression and activation in human colon cancer. , 1999, Anticancer research.
[34] R. Conaway,et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[35] N. Cheung,et al. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. , 2000, Cancer research.
[36] R. Bernards,et al. Distinct Initiation and Maintenance Mechanisms Cooperate to Induce G1 Cell Cycle Arrest in Response to DNA Damage , 2000, Cell.
[37] C. Amos,et al. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. , 2000, Cancer research.
[38] A. Koong,et al. Candidate genes for the hypoxic tumor phenotype. , 2000, Cancer research.
[39] C. Sherr. The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.
[40] N M Hjelm,et al. Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. , 2000, British journal of neurosurgery.
[41] G. Hou,et al. Type VIII collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury. , 2000, The American journal of pathology.
[42] A. Harris,et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling , 2000, Oncogene.
[43] Eamonn R. Maher,et al. Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.
[44] N. Cheung,et al. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. , 2000, The American journal of pathology.
[45] M. Ivan,et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.
[46] P. Ratcliffe,et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.
[47] S. Petersen,et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization , 2001, British Journal of Cancer.
[48] M. Dictor,et al. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report. , 2001, Acta oncologica.
[49] Patricia A. Pioli,et al. The Von Hippel-Lindau Protein Interacts with Heteronuclear Ribonucleoprotein A2 and Regulates Its Expression* , 2001, The Journal of Biological Chemistry.
[50] M. Ivan,et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. , 2001, Human molecular genetics.
[51] N. Minato,et al. The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C* , 2001, The Journal of Biological Chemistry.
[52] J. Westwick,et al. Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. , 2001, Molecular cell.
[53] Kenneth M. Yamada,et al. Fibronectin, integrins, and growth control , 2001, Journal of cellular physiology.
[54] C. Amos,et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. , 2001, Journal of the National Cancer Institute.
[55] H. Yee,et al. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. , 2001, Human pathology.
[56] C. Albanese,et al. TGFbeta and PTHrP control chondrocyte proliferation by activating cyclin D1 expression. , 2001, Molecular biology of the cell.
[57] H. Gröne,et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. , 2001, Cancer research.
[58] S. Clifford,et al. Von Hippel-Lindau disease: clinical and molecular perspectives. , 2001, Advances in cancer research.
[59] Takeshi Kishida,et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect , 1995, Human Genetics.